Key points are not available for this paper at this time.
Objective This study aimed to investigate the prevalence of comorbidity, multimorbidity and mental health disorders in patients with systemic lupus erythematous (SLE) and the association with patient reported physical and mental outcome scores (PROMIS). Methods Data from the COVAD survey was utilised for analysis. Comorbidities including cardiovascular disease (ischaemic heart disease, hypertension, hypercholesterolaemia), diabetes, respiratory disease (interstitial lung disease, chronic obstructive pulmonary disease), chronic liver and renal failure were included. Comorbidity was categorised into 1. No comorbidities (nil); 2. Single comorbidity (SM); 3. Basic multimorbidity (BM, defined as two or more comorbidities); and 4. Complex multimorbidity (CM, defined as three or more chronic conditions affecting three different organ systems).1 The occurrence of mental health comorbidities (MHC) including anxiety and depression was evaluated separately. The association between prevalence of comorbidity and patient reported outcome score were analysed ANOVA, Chi square test and multivariate linear regression. Results 1292 patients with SLE were included in this study. As shown in table 1, 41.56% of patients had at least one comorbidity (29.8% SM, 8.59%, BM, 3.17% CM). The complexity of comorbidity increased with age (pConclusions In this study, complex comorbidities were associated with lower patient reported outcomes scores relating to physical function and mental health. Increased steroid use (particularly at high dose) associated with CM, indicating either potential glucocorticoid related damage or more active disease. Female gender was protective and hydroxychloroquine use was associated with fewer comorbidities, supporting previous evidence. This study underscores the substantial need for insights into addressing comorbidities in SLE, and tailoring treatment for holistic patient management globally. Reference Harrison C, Britt H, Miller G, et al. Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice. BMJ Open 2014;4:e004694. Declaration of interest ALT has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly, and holds research grants from Pfizer and Lilly. IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG.JBL has received speaker honoraria/participated in advisory boards for Sanofi Genzyme, Roche, and Biogen. None is related to this manuscript. JD has received research funding from CSL Limited. NZ has received speaker fees, advisory board fees, and research grants from Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre; none are related to this manuscript. RA has a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therapeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio. Rest of the authors have no conflict of interest relevant to this manuscript.
Sukhija et al. (Fri,) studied this question.